Focus on Infectious Disease
  • Saved
Novel STAT1 Variants in Japanese Patients with Isolated Mendelian Susceptibility to Mycobacterial Diseases - Journal of Clinical Immunology

Novel STAT1 Variants in Japanese Patients with Isolated Mendelian Susceptibility to Mycobacterial Diseases - Journal of Clinical Immunology

Source : https://link.springer.com/article/10.1007/s10875-022-01396-1

Purpose Heterozygous dominant-negative (DN) STAT1 variants are responsible for autosomal dominant (AD) Mendelian susceptibility to mycobacterial disease (MSMD). In this paper, we describe eight MSMD cases from four kindreds in...


Conclusions: Conclusion: Four kindred MSMD subjects with 3 novel variants and 1 known variant in STAT1 were identified in this study. AD STAT1 deficiency might be prevalent in Japanese patients with BCG-associated MSMD.


  • Saved
Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2

Chemosensory deficits are best predictor of serologic response among individuals infected with SARS-CoV-2

Source : https://doi.org/10.1371/journal.pone.0274611

Objective Smell and taste alteration are closely linked to infection with SARS-CoV-2 and may be associated with a more indolent disease course. Serologic response rates among individuals with mild disease...



Conclusion: Subjective chemosensory dysfunction, as self-reported smell or taste deficiency, is highly predictive of serologic response following SARS-CoV-2 infection. This information may be useful for patient counseling. Additional longitudinal research should be performed to better understand the onset and duration of the serologic response...

  • Saved
Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy

Monoclonal Antibodies for Treatment of SARS-CoV-2 Infection During Pregnancy

Source : https://doi.org/10.7326/M22-1329

If the address matches an existing account you will receive an email with instructions to reset your password.



Conclusion: In pregnant persons with mild to moderate COVID-19, adverse events after mAb treatment were mild and rare. There was no difference in obstetric-associated safety outcomes between mAb treatment and no treatment among persons who delivered. There was no difference in 28-day COVID-19–associated outcomes and non-COVID-19–related...

  • Saved
Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study

Effectiveness of mRNA-1273, BNT162b2, and BBIBP-CorV vaccines against infection and mortality in children in Argentina, during predominance of delta and omicron covid-19 variants: test negative, case-control study

Source : https://doi.org/10.1136/bmj-2022-073070

Objective To estimate the effectiveness of a two dose vaccine schedule (mRNA-1273, BNT162b2, and BBIBP-CorV) against SARS-CoV-2 infection and covid-19 related death and short term waning of immunity in children...



Conclusion: Our study highlights that a probability score for GCA derived from a large multi-centre cohort of patients who were biopsy positive predicts ultrasound positivity with similar accuracy. Our work reveals that scoring systems are not infallible but can be helpful in guiding clinical decision making.

  • Saved
Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir - PubMed

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/36472873/

In this cohort study, viral rebound was uncommon in patients taking molnupiravir or nirmatrelvir-ritonavir and was not associated with increased risk of mortality. Given these findings, novel oral antivirals should...



Conclusions and Relevance: In this cohort study, viral rebound was uncommon in patients taking molnupiravir or nirmatrelvir-ritonavir and was not associated with increased risk of mortality. Given these findings, novel oral antivirals should be considered as a treatment for more patients with COVID-19 in the early phase of the infection.